nivolumab,ipilimumab
BMS
['nivo', 'ipi/']
adjuvant ipi/nivo did not dfs or os compared to placebo, but exploratory pd-l1 biomaker work looks striking (&lt;20% pd-l1 +ve). hr 0.4 in +ve &amp; 1.1 in -ves. similar pfs results in 1st line ipi/nivo 214 study. care1 trial will test ipi/nivo vs vegf/pd1 in pd-l1 +ves #asco2023 
Interested in Urology Cancers, biomarkers and drug development.